Press release

DSM completes acquisition of stake in Andre Pectin (China)

Heerlen, NL, 09 Oct 2013 08:15 CEST

Royal DSM, the global Life Sciences and Materials Sciences company, announced today that it has completed the acquisition of a 19% equity interest in Yantai Andre Pectin Co. Ltd. (Andre Pectin), a China based producer of texturing ingredients. DSM announced this acquisition on 5 May 2013.

DSM had previously acquired a 10% stake in Andre Pectin from Hony Capital. DSM’s total interest in Andre Pectin is now 29%. The parties have agreed that DSM has option rights to increase its stake in Andre Pectin to a majority stake at a later stage.

Andre Pectin, headquartered in Yantai (Shandong Province, China), was established in 2003 and is active in the manufacturing and sale of apple and citrus pectin, a key food hydrocolloid providing texture, as well as pectin related food products. Andre Pectin realizes annual net sales of around €30 million. As the only successful global pectin market entrant in the past 20 years, Andre Pectin is the only significant pectin manufacturer in Asia with premier access to the world’s fastest growing specialty food ingredients market.

With a market size of around €6 billion with an annual average growth rate of 3-5%, the global hydrocolloids market provides an attractive growth area to leverage DSM’s bio-ingredients capabilities and global customer access. Some food hydrocolloids, such as pectin and gellan gum possess unique properties that are highly relevant to a broad range of processed and healthy food applications.

DSM’s investment in Andre Pectin, synergistically combined with the previously acquired gellan gum assets based in China, creates a China-based hydrocolloids growth platform, in line with DSM’s strategy for the Nutrition cluster, Continued Value Growth.

For more information

Lieke de Jong-Tops

Senior Communications Manager
+31 45 578 2420
media.contacts@dsm.com

Dave Huizing

Vice President Investor Relations
+31 45 578 2864
investor.relations@dsm.com

Media Relations

+31 45 578 2420

Investor Relations

+31 45 578 2864

This site uses cookies to store information on your computer.

Learn more